Workflow
Veracyte(VCYT)
icon
Search documents
Veracyte(VCYT) - 2023 Q4 - Earnings Call Transcript
2024-02-23 02:24
Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Dustin Scaringe - William Blair Matt Sykes - Goldman Sachs Puneet Souda - Leerink Partners Operator Good day, and thank you for standing by. Welcome to the Veracyte Fourth Quarter and Full Year 2023 Financial R ...
Veracyte(VCYT) - 2023 Q4 - Earnings Call Presentation
2024-02-22 22:24
| --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Q4 2023 Business and Financial Presentation | | | | | | | | February 22, 2024 | | | | | | | This presentation contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with re ...
Veracyte(VCYT) - 2023 Q3 - Quarterly Report
2023-11-08 13:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...
Veracyte(VCYT) - 2023 Q3 - Earnings Call Transcript
2023-11-08 01:57
Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tristan Ribar – Vice President-Finance Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Conference Call Participants Puneet Souda – Leerink Sung Ji Nam – Scotiabank Mason Carrico – Stephens Inc Operator Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2023 Financial Results Webcast. At this time all participants are in a listen-only mod ...
Veracyte(VCYT) - 2023 Q2 - Quarterly Report
2023-08-09 20:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 20-5455398 (State or other ...
Veracyte(VCYT) - 2023 Q2 - Earnings Call Transcript
2023-08-09 02:05
Veracyte, Inc. (NASDAQ:VCYT) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Shayla Gorman - Director, IR Marc Stapley - CEO & Director Rebecca Chambers - EVP & CFO Conference Call Participants Matthew Sykes - Goldman Sachs Group Puneet Souda - Leerink Partners Sung Ji Nam - Scotiabank Jacob Krahenbuhl - Stephens Inc. Joseph Conway - Needham & Company Operator Good day, and thank you for standing by. Welcome to the Veracyte Second Quarter 2023 Financial Results Conference Cal ...
Veracyte(VCYT) - 2023 Q2 - Earnings Call Presentation
2023-08-09 00:29
veracyte. 8/8/2023 1 Q2 2023 Business and Financial Presentation August 8, 2023 © Veracyte, Inc. All rights reserved. Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue for 2023 and other financial and operating results and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our tests and products, including our biopharma atlas, f ...
Veracyte(VCYT) - 2023 Q1 - Quarterly Report
2023-05-05 12:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Delaware 20-5455398 6000 ...
Veracyte(VCYT) - 2023 Q1 - Earnings Call Transcript
2023-05-05 02:43
Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Mason Carrico - Stephens, Inc. Matt Sykes - Goldman Sachs Andrew Brackmann - William Blair Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper - Raymond James Operator Good day and thank you for standi ...
Veracyte(VCYT) - 2023 Q1 - Earnings Call Presentation
2023-05-04 23:46
veracyte. 5/4/2023 1 Q1 2023 Business and Financial Presentation May 4, 2023 © Veracyte, Inc. All rights reserved. Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue for 2023 and other financial and operating results and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our tests and products, including our biopharma atlas, for ...